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Objectives: To evaluate the efficacy and safety of 2.5 mg and 5 mg mifepristone during 
3 months for the treatment of uterine fibroids before surgery.
Design: Multicenter randomized clinical trial.
Locations: Eusebio Hernández Hospital, Havana, Cuba and the Alemán Hospital, Managua, 
Nicaragua.
Subjects: Included in the study were 146 women with symptomatic uterine fibroids.
Treatment: Group I: half a tablet of 5 mg (2.5 mg) mifepristone taken orally every 24 hours, 
and Group II: one tablet of 5 mg mifepristone taken orally every 24 hours over a period of 
3 months in both groups. Two endometrial biopsies were performed.
Variables to evaluate efficacy: Increase in average hemoglobin, changes in fibroid and 
uterine volume, and symptomatic improvement.
Results: The average hemoglobin at the end of treatment was 0.6 g/dL greater in the 5 mg 
mifepristone group (P = 0.033). In both groups there were similar reductions in fibroid volumes. 
Clinical improvement was more significant in the 5 mg group.
Conclusion: The dose to be used should be 5 mg.
Keywords: mifepristone, leiomyoma, fibroid  , antiprogestins
Introduction
Approximately half of women aged 35–49 years have uterine fibroids and almost half 
of them have heavy bleeding often causing severe anemia.1,2 Every year more than 
200,000 hysterectomies due to uterine myomas are performed in the United States.3 
The absence of an efficient and safe medication capable of being administered repeat-
edly contributes to the increase in the number of surgical interventions.
At one time it was thought that only estrogens played a part in the development 
of uterine myomas, now we know that progesterone also plays its part in their growth 
and that mifepristone, by inhibiting the latter, influences this development.4–6
Many studies show the efficacy of mifepristone in doses of 50, 25, or 10 mg for 
the treatment of uterine fibroids, both with respect to reducing the fibroid size and/or 
improving their symptoms.7–15
There is enough existing scientific evidence to show that low doses of only 5 mg 
mifepristone are as efficient and safe as those of 10 mg.9,14,16–20
Eisinger et al,21 in a pilot study with only 17 cases and using doses of 2.5 mg, 
obtained results notably inferior in some respects to those obtained with 5 mg and 
in other lesser variables results which are similar or close in effectiveness.21 Doses 
of 2 mg and 5 mg mifepristone were used for contraception by Baird et al.22
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The aim of this study was to facilitate surgery by   improving 
hematological conditions and reducing the volume of any 
such surgery.
Material and methods
Design
This is a multicenter randomized clinical trial to evaluate 
the efficacy and safety of daily doses of 2.5 mg and 5 mg 
mifepristone over a 3-month period for treating uterine 
fibroids before surgery. The clinical trial was carried out 
in the Eusebio Hernández Hospital in Havana, Cuba and 
in the Alemán Hospital in Managua, Nicaragua. The study 
protocol was approved by the respective research committees 
at each hospital. All subjects gave their informed consent to 
participate in the study.
The clinical trial was performed in accordance with the 
revised version of the Declaration of Helsinki (2004) and 
adhered to good clinical practice standards. The trial began 
in November 2009 and the last subject included was evalu-
ated in May 2011.
The use of a placebo group was discarded so as not to 
deprive the subjects of any therapeutic opportunity as there 
is published evidence that mifepristone in low doses reduces 
fibroid size, produces relief of associated symptomatology, 
and improves the general condition of the subject prior to 
surgery. Subjects were recruited from the hospital gyneco-
logical classification consultancies.
Subjects
Women of childbearing age with symptomatic uterine fibroids 
requiring treatment to improve their general condition before 
undergoing hysterectomy or myomectomy were eligible for 
the trial. The inclusion criteria was: (a) symptomatic uterine 
leiomyomas, (b) indication for surgery (hysterectomy or 
myomectomy), and (c) agreement to record on a monthly basis 
all vaginal bleeding episodes, mifepristone side effects, and 
to have ultrasound examinations at every evaluation session. 
The exclusion criteria was: (a) pregnancy or the desire to get 
pregnant, (b) breastfeeding, (c) hormonal contraception or any 
hormonal therapy in the last 3 months, (d) signs or symptoms 
of pelvic inflammation, (e) adnexal tumors, (f) suspicion or 
diagnosis of cervical–uterine or ovarian cancer, (g) signs or 
symptoms of mental illness, (h) unexplained genital bleeding, 
(i) anemia due to sickle-cell disease, (j) suffering from a seri-
ous illness, and (k) antiprogesterone contraindications. After 
evaluation of inclusion and exclusion criteria and gathering 
and   submitting all the information needed to participate in the 
trial, the subjects signed the informed consent.
Treatment
Group I (2.5 mg mifepristone)
Oral administration of half a 5 mg tablet (2.5 mg) of mife-
pristone every 24 hours for 3 months.
Group II (5 mg mifepristone)
Oral administration of one tablet of 5 mg mifepristone every 
24 hours for 3 months.
The mifepristone was supplied by Litaphar Laboratories 
(Azpeitia, Spain), in individual 5 mg tablets. Treatment 
began in both groups between the second and fourth days of 
  menstruation. At every evaluation session the subjects were 
given a phial containing the medication they required up until 
the next visit and this continued until the end of treatment.
Treatment assignment
The subjects satisfying all requirements were included in 
the trial in the order they joined it and were assigned to 
one or other of the treatment groups by means of a random 
computer-generated list. Centralized in Havana, staff not 
directly involved in the trial prepared for both participant 
centers, opaque and sequentially numbered sealed envelopes, 
each one containing a card indicating “mifepristone 2.5 mg” 
or “mifepristone 5 mg.” Once the subject had been included, 
the envelope corresponding to her trial inclusion number was 
opened and she was assigned to the treatment indicated on 
the card contained within.
Examinations performed
Complete gynecological examination with pregnancy test, 
Pap test, and abdominal or vaginal ultrasound examination 
of the uterus prior to commencement and every 30 days until 
termination of treatment. Fibroid volume was calculated using 
the formula: 0.523 × ABC where A, B, and C are the fibroid 
diameters in each of the three planes and volume is expressed 
in cubic centimeters.8 If the subject had more than one myoma, 
measurement was taken of the biggest myoma and its varia-
tions were used to evaluate the effect of mifepristone on the 
fibroid. The total volume of the uterus was calibrated using 
the previously mentioned formula. Endometrial thickness in 
millimeters was also measured by ultrasound. All ultrasound 
calibrations were performed using ultrasound diagnostic 
equipment (SSD-4000; Aloka Co, Ltd, Mitaka-shi, Tokyo, 
Japan) and carried out by two ultrasound medical specialists. 
Measurements taken in the various follow-up periods were car-
ried out without the specialists knowing the results of previous 
calibrations, they only knew the location of the myoma they 
had to measure if the subject had more than one fibroid.
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Blood samples were taken for hematological studies 
and liver function at the first visit and every 30 days until 
termination of treatment. It was decided beforehand that 
any subject presenting transaminase alterations of values 
over three times their normal maximum limit, in line with 
US Food and Drug Administration (FDA) recommendations, 
would be eliminated from the trial.23
Given the climate of estrogenic predominance stimulated 
by mifepristone due to the elimination of gestagen action, the 
risk of endometrial hyperplasias appearing was considered to 
be greater. To control this phenomenon and/or the appearance 
of what Mutter et al and Horne and Blithe call “endometrial 
changes associated to progesterone receptor modulators 
(PAECs),”24,25 endometrial biopsies were performed before 
and after treatment only on those subjects who decided not to 
have surgery for whatever reason. We report the result of the 
anatomopathological study of the endometrium performed 
on the subjects’ surgically-removed uterus. An endometrial 
biopsy was taken during surgery from subjects undergoing 
myomectomy.
Once treatment was terminated the subjects underwent 
surgery between 3 and 10 days later. At each visit the sub-
jects were given a form where they were to record bleeding 
episodes, side effects of mifepristone, and any other relevant 
information; these forms were handed in at the following 
visit.
Variables to evaluate efficacy
The main variable for evaluating efficacy was the average 
hemoglobin (g/dL) at the end of treatment in the 2.5 mg and 
5 mg mifepristone groups. It was measured at the begin-
ning and every 30 days until termination of treatment. As 
secondary variables of efficacy, measurement of the changes 
registered in the fibroid and uterus dimensions was performed 
using ultrasound at each evaluative consultancy. Other vari-
ables measured were: (a) changes in the prevalence and inten-
sity of pelvic pain and hypermenorrhea, both calibrated by 
a visual analog scale from 0 to 10 in which 0 represented 
the absence of symptoms and 10 their maximum value and 
determined by the subject herself; these symptoms were 
evaluated prior to commencement of treatment and every 
30 days until termination, and (b) changes in the prevalence 
of pelvic pressure, urinary alterations, rectal and/or lumbar 
pain, and metrorrhagia which were measured at the beginning 
of treatment and every 30 days until termination.
We consider metrorrhagia to be the bleeding that occurs 
between menstrual periods; we consider hypermenorrhea to 
be menstruation lasting a few days with the subject suffering 
a greater than normal blood loss. “Pelvic pressure” is the 
term used by most authors to define a sensation of pressure 
or something tightening or occupying the pelvis; “irregular 
bleeding” is considered to be the bleeding incurred during 
treatment in the form of spotting or bleeding heavier than 
spotting.
Variables to evaluate safety
The variables to evaluate safety were (a) changes in endo-
metrial thickness measured by ultrasound (mm), (b) side 
effects of mifepristone: amenorrhea, hot flushes, nausea, 
dizziness, vomiting, and fatigue, (c) changes in liver 
transaminase levels: aspartate aminotransferase (AST) and 
alanine aminotransferase (ALT); these three parameters were 
evaluated every month until termination of treatment, and 
(d) frequency of histological endometrial anomalies at the 
end of treatment.
Number of patients to be included
In administering 5 mg mifepristone over 3 months the 
average hemoglobin was expected to be 1.0 g/dL higher at 
the end of treatment in subjects taking 5 mg mifepristone 
than in those taking 2.5 mg. It was assumed the variances 
were similar and these were considered equal to 1.6 g/dL, 
based on other trials with mifepristone in the treatment of 
uterine fibroids. Working on previous suppositions and so 
as to guarantee a power of 90% in a two-tailed test with 
a significance level of 0.05, a minimum sample size of 
55 subjects in each treatment group was required.26 The 
total sample size was increased by approximately 20% 
(140 patients in all, 70 subjects in each group) in order to 
counter subject dropouts during treatment.
Statistical analysis
To evaluate the homogeneity of the two participant centers 
and the treatment groups, use was made of the one-way 
analysis of variance, the t-test, Pearson’s chi-square test, and 
the normal approximation for proportions. Analysis of 
hemoglobin changes was performed using the t-test for 
independent samples (comparison between the treatment 
groups) and the t-test for paired samples (comparisons 
within each mifepristone group). Differences between the 
treatment groups regarding fibroid and uterine volumes 
and endometrial thickness in each evaluative period were 
analyzed by t-test. The t-test was used to analyze pelvic 
pain and hypermenorrhea in only those subjects who had 
symptoms prior to treatment. Side effects of mifepristone 
are presented in descriptive statistical graphs and normal 
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approximation for proportions was used in comparing 
treatments. In all cases P , 0.05 was considered significant. 
The data was processed using SPSS software (v. 11.5; SPSS 
Inc, Chicago, IL).
Results
Inclusion and compliance  
with the treatment
In all, 168 subjects in both centers were referred to the trial, 
22 of them failed to satisfy the inclusion criteria. One hundred 
forty-six of 168 (86.9%) subjects were included, with 71 and 
75 in the 2.5 mg and 5 mg mifepristone groups, respectively 
(see Figure 1).
In Havana, of the 47 subjects included in the 2.5 mg mife-
pristone group there were nine dropouts: four did not attend 
the first evaluative consultation, one underwent surgery 
due to fibroid necrobiosis before completing the first month 
of treatment, three abandoned treatment in the first month 
prior to surgery, and one abandoned treatment at the end of 
the second month. Of the 48 included in the 5 mg group there 
were two dropouts: one due to surgery for fibroid necrobiosis 
before completing the first month and the other abandoned 
the trial in the second month of treatment.
In Managua, of the 24 subjects included in the 2.5 mg 
group there were three dropouts: two abandoned treatment 
between the second and third month and one dropped out due 
to heavy bleeding during the first month of treatment with 
mifepristone. Of the 27 included in the 5 mg group there 
were two dropouts: one due to fibroid expulsion in the first 
month and one due to elevated transaminases after 1 month 
of treatment (60 and 72 IU of AST and ALT), respectively. 
In total, in the two centers there were twelve of 71 (16.9%) 
and four of 75 (5.3%) dropouts in the 2.5 mg and 5 mg 
groups, respectively (P = 0.01). Data was processed in an 
“intention-to-treat basis” and the information on patients who 
abandoned the trial is included in the results in the evaluative 
periods in which they took mifepristone.
Initial variables and comparison  
between treatment groups
Table 1 shows the general characteristics of all the subjects 
included in the clinical trial. There were no significant 
Primary health units and classification consulting departments from hospitals identified women with symptomatic leiomyomas, n = 168
The office of the clinical trial accepted women for enrollment; endometrial biopsy and ultrasound of leiomyomas and uterus
performed and blood sample taken, n = 146; (87%)
Women randomized to receive mifepristone 2.5 mg
daily for 3 months, n = 71
Women randomized to receive mifepristone 5 mg
daily for 3 months, n = 75
Ultrasound of leiomyomas and uterus performed and
blood sample taken, at 3 months treatment, n = 58
Ultrasound of leiomyomas and uterus performed and
blood sample taken, at 3 months treatment, n = 67
Underwent surgery, n = 57
1 refused surgery
Underwent surgery, n = 63
4 refused surgery
Figure 1 Flow chart for the trial.
Table 1 Subject characteristics by mifepristone group
Characteristics 2.5 mg 
(n = 71)
5 mg 
(n = 75)
Age 42.3 ± 5.8 42.0 ± 6.7
Body mass index (kg/m2) 26.2 ± 4.5 27.2 ± 4.8
Gravidity 3.3 ± 1.9 3.1 ± 1.8
Parity 2.0 ± 1.1 2.1 ± 1.4
Abortion 1.8 ± 1.8 1.8 ± 1.3
Fibroids volume (mL) 106 ± 156 115 ± 114
Uterine volume (mL) 426 ± 323 527 ± 373
Endometrial thickness (mm) 6.7 ± 2.1 7.3 ± 2.7
Aspartate aminotransferase (IU) 22.6 ± 8.7 20.5 ± 9.8
Alanine aminotransferase (IU) 21.7 ± 10.1 20.2 ± 10.9
Hemoglobin (g/dL) 10.7 ± 2.2 10.9 ± 1.6
Hemoglobin (,10.0 g/dL) 23 (32.4) 18 (24.0)
Race
White 23 (32.4) 18 (24.0)
Black 18 (25.4) 18 (24.0)
Afro-Cuban 30 (42.0) 39 (52.0)
Note: Data presented as averages ± standard deviation+ or n(%).
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  differences between the treatment groups for any of them. Nor 
were there significant differences between the centers save for 
two exceptions; there were significantly (P , 0.001) less black 
subjects in Managua, two of 51 (3.9%), than in Havana, 34 of 
95 (35.8%); the fibroid volumes in the subjects in Managua 
were 2.1 times less than in the patients in Havana (P = 0.003); 
and there were no significant differences in the average uter-
ine volumes between the participant centers, nor between the 
mifepristone groups. No subject was diagnosed with fibroid-
associated sterility. There were 15 of 71 (21.1%) and 19 of 
75 (25.3%) subjects with only one myoma in the 2.5 mg and 
5 mg mifepristone groups, respectively (P = 0.274), and no sig-
nificant differences between the participant centers (P . 0.05). 
In total, the fibroids studied were made up as follows: 30 of 146 
(20.6%) subserous, six of 146 (4.1%) submucous, and 110 of 
146 (75.3%) intramural, and there were no significant differ-
ences between the mifepristone groups (P = 0.165).
Once treatment was over, surgery was refused by four of 
63 (6.3%) of the 5 mg group in Havana and one of 24 (4.2%) 
of the 2.5 mg group in Managua (P = 0.348).
Efficacy
The average hemoglobin levels at the end of treatment 
were 11.3 ± 1.7 and 11.9 ± 1.1 g/dL in the 2.5 mg and 
5 mg   mifepristone groups, respectively (P = 0.033).   
In the 2.5 mg group the initial hemoglobin average was 
10.7 ± 2.2 g/dL and the final one was 11.3 g/dL (P = 0.03); in 
the 5 mg group the initial hemoglobin average was 10.9 g/dL 
and the final average was 11.9 ± 1.1 g/dL (P , 0.001).
Prior to treatment the percentages of subjects with 
hemoglobin , 10.0 g/dL were 23 of 71 (32.4%) and 18 of 
75 (24.0%) in the 2.5 mg and 5 mg mifepristone groups, 
respectively (P = 0.13); there were no significant differ-
ences between the centers and treatment groups. Thirty days 
after beginning treatment there were 20 of 59 (33.9%) and 
15 of 65 (23.1%) subjects with hemoglobin , 10.0 g/dL 
in the 2.5 mg and 5 mg mifepristone groups, respectively 
(P = 0.091). Two months into treatment the subjects with 
hemoglobin ,10.0 g/dL were 14 of 54 (24.6%) and ten of 
65 (15.4%) in the 2.5 mg and 5 mg mifepristone groups, 
respectively (P = 0.077).
At the end of treatment, there were seven of 50 (14%) and 
three of 63 (4.8%) subjects with hemoglobin , 10.0 g/dL 
in the 2.5 mg and 5 mg mifepristone groups, respectively 
(P = 0.043). In the 2.5 mg group, the percentage of subjects 
with ,10.0 g/dL hemoglobin levels was significantly 
reduced by the end of treatment (P = 0.011), and in the 
5 mg mifepristone group it was very significant (P , 0.001). 
Table 2 Changes in fibroid measurements (cm3) by treatment groups
Evaluation Group n Mean ± standard  
deviation
95% confidence  
interval for mean
Cumulative  
reduction+
P*
Before treatment 2.5 mg 48 119 ± 107 87–150 0.402
5 mg 60 140 ± 144 103–177
1 month treatment 2.5 mg 48   87 ± 95 59–114 26.7% 0.917
5 mg 60   85 ± 102 60–112 39.3%
2 months treatment 2.5 mg 48   75 ± 75 54–97 36.9% 0.853
5 mg 60   72 ± 90 50–96 48.6%
3 months treatment 2.5 48   73 ± 82 49–96 38.7% 0.556
5 mg 60   64 ± 76 44–84 54.3%
Notes: *t-test (analysis of variance); +concerning value before treatment in the same group.
Table 3 Changes in uterine measurements (cm3) by treatment groups
Evaluation Group n Mean ± standard  
deviation
95% confidence  
interval for mean
Cumulative  
reduction+
P*
Before treatment 2.5 mg 48 384 ± 246 313–456 0.019
5 mg 60 538 ± 390 437–639
1 month treatment 2.5 mg 48 377 ± 297 292–464 1.8% 0.228
5 mg 60 449 ± 314 368–530 16.5%
2 months treatment 2.5 mg 48 359 ± 375 286–504 6.5% 0.866
5 mg 60 369 ± 233 308–429 31.4%
3 months treatment 2.5 mg 48 347 ± 267 270–425 9.6% 0.295
5 mg 60 407 ± 357 314–499 24.3%
Notes: *t-test (analysis of variance); +concerning value before treatment in the same group.
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At the end of treatment, the proportion of subjects with 
hemoglobin . 10.0 g/dL in the 5 mg group in Nicaragua 
was significantly greater than in the 2.5 mg group in Havana 
(P = 0.013); in the remaining comparisons there were no 
significant differences.
Tables 2 and 3 compare the dimensional changes in 
fibroid and uterine volumes during the trial evaluative periods 
for the subjects with the relevant observations. Three months 
into treatment fibroid volume was not reduced, compared to 
its initial value, in six of 48 (12.5%) and five of 60 (8.3%) 
subjects in the 2.5 mg and 5 mg groups, respectively 
(P = 0.238). At the end of treatment, compared to pretreat-
ment values, uterine volume was not reduced in 14 of 48 
(29.2%) and 16 of 60 (26.7%) subjects in the 2.5 mg and 
5 mg groups, respectively (P = 0.387).
Table 4 shows the changes in fibroid symptom prevalence 
before treatment and at each evaluative period. Tables 5 
and 6 show the changes in the prevalence and intensity of 
pelvic pain and hypermenorrhea.
Side effects of mifepristone
There was amenorrhea in 28 of 60 (46.7%) and 35 of 
67 (52.2%), 39 of 55 (70.1%) and 54 of 65 (83.1%), 42 of 
50 (84.0%) and 58 of 63 (92.0%), subjects in the 2.5 mg and 
5 mg groups at the consultations after 30, 60, and 90 days 
(P = 0.265, P = 0.056, and P = 0.091), respectively.
Hot flushes were reported at least once during treatment by 
14 of 24 (51.9%) and ten of 27 (37.0%) subjects in the 2.5 mg 
and 5 mg groups in Managua, respectively (P = 0.064); hot 
flushes were reported in the three evaluative consultations 
by 14 subjects, seven in each mifepristone group.
Hot flushes were reported at least once during treatment 
by nine of 38 (23.6%) and six of 42 (14.3%) in the 2.5 mg and 
5 mg groups in Havana, respectively (P = 0.141). Hot flushes 
were reported in the three evaluative consultations by one 
subject in the 2.5 mg group and by none in the 5 mg group.
In total, in both centers hot flushes were reported at least 
once during treatment by 23 of 62 (37.1%) and 16 of 69 
(23.2%) subjects in the 2.5 mg and 5 mg groups, respectively 
(P = 0.041); hot flushes were reported in the three evaluative 
consultations by eight and seven subjects in the 2.5 mg and 
5 mg mifepristone groups, respectively.
At some point during treatment the following side effects 
of mifepristone were reported: (a) nausea by four of 50 (8.0%) 
and four of 63 (6.3%) subjects in the 2.5 mg and 5 mg groups, 
respectively (P = 0.367); (b) vomiting by two of 50 (4.0%) 
and two of 63 (3.2%) subjects in the 2.5 mg and 5 mg groups, 
respectively (P = 0.42); (c) feeling of fatigue by twelve of 
50 (24.0%) and seven of 63 (11.1%) subjects in the 2.5 mg 
and 5 mg groups, respectively (P = 0.034).
During the treatment period there were four of 71 
(5.6%) subjects in the 2.5 mg mifepristone group with 
elevated liver transaminase levels: between 47 and 78 IU 
for AST and between 51 and 62 IU for ALT, (reference 
levels 46 and 49 for AST and ALT, respectively). In the 
5 mg group there were six of 75 (8.1%) elevated transami-
nases: between 51 and 72 IU for AST and between 53 and 
62 for ALT.
Table 4 Prevalence of fibroid symptoms before, after 30, 60, and 
90 days treatment by groups
Treatment P*
2.5 mg 5 mg
Pelvic pain
Before treatment 56 (83.1) 60 (80.0) 0.315
30 days after 29 (48.3) 35 (52.2) 0.330
60 days after 23 (41.8) 24 (36.9) 0.292
90 days after 19 (38.0) 13 (21.3) 0.023
Pelvic pressure
Before treatment 46 (64.8) 48 (64.0) 0.460
30 days after 30 (50.0) 23 (34.3) 0.037
60 days after 20 (36.4) 13 (20.0) 0.023
90 days after 16 (32.0) 14 (23.0) 0.143
Urinary symptoms
Before treatment 45 (63.4) 47 (62.7) 0.464
30 days after 30 (50.0) 34 (50.7) 0.467
60 days after 23 (41.8) 20 (30.8) 0.104
90 days after 11 (22.0) 13 (21.3) 0.465
Lumbar pain
Before treatment 56 (78.9) 52 (69.3) 0.095
30 days after 28 (46.7) 35 (52.2) 0.265
60 days after 25 (45.5) 22 (33.8) 0.097
90 days after 20 (40.0) 15 (24.6) 0.041
Rectal pain
Before treatment 30 (42.2) 28 (37.3) 0.272
30 days after 13 (21.7) 10 (16.7) 0.162
60 days after 10 (18.2) 5 (7.7) 0.042
90 days after 5 (10.0) 2 (3.3) 0.074
Dispareunia
Before treatment 35 (49.3) 35 (46.7) 0.375
30 days after 15 (25.0) 21 (31.3) 0.214
60 days after 11 (20.0) 11 (16.9) 0.332
90 days after 8 (16.0) 2 (3.3) 0.009
Hypermenorrhea
Before treatment 61 (85.9) 63 (84.0) 0.373
30 days after 28 (46.7) 26 (38.8) 0.186
60 days after 11 (20.0) 5 (7.7) 0.024
90 days after 4 (8.0) 5 (8.2) 0.485
Metrorrhagia
Before treatment 24 (33.8) 35 (46.7) 0.057
30 days after 7 (11.7) 12 (17.9) 0.162
60 days after 3 (5.5) 2 (3.1) 0.258
90 days after 4 (8.0) 1 (1.6) 0.054
Notes: Data presented as n(%); *Normal approximation for proportions.
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Table 7 shows changes in endometrial thickness during 
treatment.
Between the beginning and end of treatment, irregular 
vaginal bleeding at some time was reported by 19 of 63 
(30.1%) and eleven of 67 (16.4%) subjects in the 2.5 mg 
and 5 mg mifepristone groups, respectively (P = 0.032); 
the average number of days was: 6.3 ± 5.1 and 5.4 ± 4.1 in 
the 2.5 mg and 5 mg mifepristone groups, respectively 
(P = 0.601). Over the 3 months of treatment some spotting 
was reported by 29 of 63 (46.0%) and 20 of 67 (29.8%) 
subjects in the 2.5 mg and 5 mg mifepristone groups, 
respectively (P = 0.029); the average number of days 
was: 8.0 ± 7.1 and 6.3 ± 5.9 in the 2.5 mg and 5 mg mife-
pristone groups, respectively (P = 0.599). In total, there 
was irregular bleeding (spotting and/or blood) in 32 of 
63 (50.8%) and 21 of 67 (31.3%) subjects in the 2.5 mg 
and 5 mg mifepristone groups, respectively (P = 0.012); 
the average duration was 11.0 ± 10.6 and 8.8 ± 8.9 days 
in the 2.5 mg and 5 mg mifepristone groups, respectively 
(P = 0.437).
Endometrial biopsy
In the endometrial biopsies before and after treatment 
there was no diagnosis of simple hyperplasia, atypical or 
not, nor was any other pathology found and there were 
no significant differences between the two mifepristone 
groups. In the posttreatment endometrial biopsies eleven 
of 125 (8.8%) were found to be of no diagnostic use; in 
the 114 with valid results there were 16 of 56 (28.6%) and 
14 of 58 (24.1%) PAECs in the 2.5 mg and 5 mg groups, 
respectively (P = 0.296). The remaining diagnoses in both 
groups were compatible with secretory or proliferating 
endometria.
Surgery
In all, hysterectomies were performed with or without double 
adnexectomy on 51 of 57 (89.5%) and 59 of 63 (93.7%) 
subjects in the 2.5 mg and 5 mg mifepristone groups, 
respectively (P = 0.204). In six of 57 (10.5%) and four of 
63 (6.3%) subjects in the 2.5 mg and 5 mg mifepristone 
groups, respectively, myomectomies were performed. In 
the subjective evaluation of intraoperative bleeding this 
was considered to be “less than usual” in 20 of 57 (35.1%) 
and 30 of 63 (47.6%) in the cases in the 2.5 mg and 5 mg 
mifepristone groups, respectively (P = 0.082).
The surgeons considered surgery to be “easier than 
usual” in eight of 57 (14.0%) and 23 of 63 (36.5%) subjects 
in the 2.5 mg and 5 mg mifepristone groups, respectively 
(P = 0.002). The average postoperative stay in hospital 
for subjects in Cuba was 3.4 ± 5.4 and 1.4 ± 0.8 days in 
the 2.5 mg and 5 mg groups, respectively (P = 0.046). 
In those in Nicaragua, the average postoperative stay in 
hospital was 2.5 ± 1.8 and 3.3 ± 2.8 days in the 2.5 mg and 
5 mg groups, respectively (P = 0.345). In Table 8 we have 
Table 5 Changes in pelvic pain intensity during evaluation
Treatment
Start 30 days 60 days 90 days
n (n = 60; n = 59) (n = 44; n = 52) (n = 44; n = 52) (n = 44; n = 52)
2.5 mg 
Reduction (%)
6.9 ± 2.9 
–
3.6 ± 3.9 
47.8
2.4 ± 3.5 
65.2
2.0 ± 3.0 
71.0
5 mg 
Reduction (%)
7.0 ± 2.5 
–
2.9 ± 3.1 
58.6
2.1 ± 3.1 
70.0
1.0 ± 2.3 
85.7
P* 0.813 0.325 0.564 0.079
Note: *Corresponds to comparison between treatment groups.
Table 6 Changes in hypermenorrhea intensity during evaluation
Treatment
Start 30 days 60 days 90 days
n (n = 43; n = 55) (n = 43; n = 55) (n = 43; n = 55) (n = 43; n = 55)
2.5 mg 
Reduction (%)
8.5 ± 2.5 
–
3.4 ± 4.0 
60.0
1.5 ± 3.1 
82.4
0.5 ± 1.9 
94.1
5 mg 
Reduction (%)
8.8 ± 2.0 
–
3.2 ± 3.9 
63.6
0.3 ± 1.2 
96.6
0.3 ± 1.1 
96.6
P* 0.454 0.866 0.024 0.455
Note: *Corresponds to comparison between treatment groups.
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presented some surgery data according to mifepristone 
groups.
Discussion
This multicenter trial presents some differences in the sub-
jects included: (1) the size of the fibroids is 2.2 times smaller 
in Nicaragua, and (2) the percentage of black subjects is much 
less in Nicaragua. In the latter study the subject age is on 
average 3 years older than in our previous studies.16–19
Despite the difference in the final hemoglobin levels 
between both groups being significant, it is only 0.5 g/dL, 
which, from a clinical point of view, is not especially impor-
tant when the data is interpreted together, but it is important 
when analyzed separately: for example, the more serious 
anemic subjects with less than 10 g/dL. In that subgroup the 
improvement is much greater and faster than in the 5 mg 
group (P = 0.04).
Doubtlessly, this improvement is related to the percent-
ages of amenorrhea in each group which, although not pre-
senting significant differences, except in the second month, 
when at the limit of statistical significance (P = 0.056), do 
observe a tendency towards greater percentages of amenor-
rhea in the 5 mg group, which might be significant with 
greater sample sizes. Our percentages of amenorrhea are 
superior to those obtained by Eisenger et al in the only study 
carried out to date with 2.5 mg which reaches only 65% after 
3 months of treatment.21
This tendency is also observed to an even greater degree 
in the percentage of subjects having irregular bleeding 
(blood + spotting) which is always significantly less in the 
5 mg group (P = 0.012). And although the difference is not 
significant the average duration of days with bleeding is also 
less (P = 0.437).
Table 4 shows that the 5 mg group as a whole experiences 
a significantly greater clinical improvement at the end of 
treatment, this greater clinical efficacy can be seen particu-
larly in pelvic pressure, rectal pain, and hypermenorrhea; that 
is to say, the subjects in the 5 mg group improve faster even 
when this clinical improvement levels out in both treatment 
groups in only one part of their symptoms. The same thing 
happens with the intensity in hypermenorrhea in the second 
month of treatment which is significantly lower in the 5 mg 
group (P = 0.02) (Table 6).
These differences are probably behind the greater number 
of dropouts in the 2.5 mg group (twelve of 71, 16.9%) com-
pared with (four of 75, 5.3%) in the 5 mg group (P = 0.01). 
Table 8 Some surgery data by mifepristone group
Surgery data Group n Mean Standard  
deviation
Min Max P
Postsurgery stay in hospital 2.5 mg 57 2.1 3.8 1 24 0.712
5 mg 63 1.9 1.9 1 11
Hemoglobin before surgery 2.5 mg 57 11.4 1.5 8.0 14.0 0.404
  5 mg 63 11.6 1.1 9.0 14.5
Hemoglobin after surgery 2.5 mg 57 10.9 1.4 7.0 14.0 0.436
5 mg 63 11.1 1.4 8.0 14.5
Length of surgery (min) 2.5 mg 57 95.5 35.4 43 178 0.173
  5 mg 63 87.4 29.2 35 148
Intraoperative bleeding (mL) 2.5 mg 57 500 216 100 1000 0.981
5 mg 63 499 239 100 1000
Note: Data presented as averages ± standard deviation.
Table 7 Changes in endometrial thickness (mm) by treatment groups
Evaluation Group n Mean ± standard  
deviation
Increment+ P*
Before treatment 2.5 mg 48 6.8 ± 2.0 0.098
5 mg 60 7.6 ± 2.8
1 month treatment 2.5 mg 48 7.8 ± 3.0 14.7% 0.873
5 mg 60 7.9 ± 3.4 3.9%
2 months treatment 2.5 mg 48 8.5 ± 2.9 25.0% 0.001
5 mg 60 10.9 ± 3.8 43.4%
3 months treatment 2.5 48 9.4 ± 3.7 38.2% 0.267
5 mg 60 10.3 ± 4.5 35.5%
Notes: *t-test (analysis of variance); +concerning value before treatment in the same group.
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This is similar to the results obtained by Eisinger et al who 
also reports a high level of dropouts (26%) when using a 
2.5 mg dosage.21
A greater efficacy in the 5 mg mifepristone group may 
also be indicated by the submucous fibroid being expelled at 
the end of the first month of treatment as well as by the greater 
number of cases that refused to undergo surgery.
The same is not the case with other secondary variables: 
fibroid volume, to name one, since the percentages in fibroid 
volume reduction in both treatment groups do not differ sig-
nificantly at the end of treatment (P = 0.55), although there 
is a marked tendency in major fibroid volume reductions in 
the 5 mg group which would probably become significant 
were the sample size increased. The same applies to uterine 
volume (P = 0.34).
The 9.6% reduction in uterine volume obtained in the 
2.5 mg group in this trial is similar to the 11% obtained by 
Eisinger et al21 in their study with 2.5 mg, but quite a lot lower 
than the average percentages in reduction obtained with a 5 mg 
dosage in other studies.16–19 There cannot be said to be a direct 
linear causal relationship between reduction in fibroid size and 
clinical improvement as, for example, in our previous trials 
there are approximately 20% of cases whose fibroids do not 
decrease and nevertheless do experience a clinical improve-
ment and the same thing happens in the present trial.13–17,19 
Something similar occurs in the study by Engman et al.8
With regard to safety, the elevated transaminases are low 
percentage-wise and of minimum clinical significance since 
the levels never rise above 100 IU at most. These percentages 
are similar to other studies.8,9,14,16–20
The side effects produced by mifepristone are similar 
in both groups, including the hot flushes which are the only 
substantial mifepristone side effect. It should be pointed out 
that the high prevalence of hot flushes (24% and 21.3% in the 
2.5 mg and 5 mg groups, respectively) obtained in this trial 
is basically due to their greater incidence in the subjects in 
Nicaragua, hovering around the 50% mark, given that in the 
subjects in Cuba it is the same as in previous trials, around 
10%. We believe that there is some bias in collecting data 
on this symptom in the Nicaraguan center. Although the 
intensity of hot flushes has never been studied, the impression 
the researchers have is that they are of an intensity, duration, 
and frequency much greater than those of the physiological 
menopause or those brought on by gonadotropin-releasing 
hormone analogs. Moreover, in none of our four clinical tri-
als published,16–19 which included around 400 subjects, has 
there been a single case of dropout from treatment due to hot 
flushes nor has treatment for such been requested.
The increase in endometrial thickness derived from the 
estrogenic predominance triggered by mifepristone shows 
no significant differences between the two treatment groups 
(P = 0.26), the average end-of-treatment values not being 
excessively over the permitted physiological limit of 8 mm.
When analyzing the surgical data of the Cuba subgroup, 
one is struck by the significant differences in the average 
postoperative hospital stay (P = 0.046). With regard to surgi-
cal variables logically, there were no differences between the 
various surgical parameters studied since these could only 
have been evident had they been compared to a group that 
did not receive mifepristone, ie, a placebo group. In this case 
significant differences would certainly have been observed 
between the sizes of the removed fibroid or uterus, ease of 
surgery, or blood loss.
The results of the posttreatment endometrial biopsies do 
not include any simple hyperplasia, atypical or not, being 
within the classical diagnostic categories or those recently 
established by Mutter and Horne, or PAECs24,25 for endome-
tria under the effect of progesterone receptor modulators like 
mifepristone. There are no significant differences between 
the two treatment groups. The percentages of histological 
changes of the PAEC type are similar to those obtained 
by Fiscella et al.27 This could represent a threshold effect; 
perhaps differences in features would appear at doses lower 
than 2.5 mg. The histological changes found in the present 
trial are similar to those observed with other progesterone 
receptor modulators like CDB-4124.28
When compared with other progesterone receptor 
modulators like ulipristal that have proved their efficacy in 
this field, our results are similar to those obtained with this 
medicine.29,30
So, therefore, this new therapeutic technique for uterine 
fibroids offers us an ongoing medical (as opposed to surgical) 
treatment. A treatment cycle administered periodically 
according to the subject’s individual response until the onset 
of the menopause. The data obtained in other studies indicate 
that this therapeutic technique could be viable.7–21
One of the weak points of this trial is not evaluating the 
impact on quality of life which is shown to have increased in 
the study by Eisinger with a dosage of 2.5 mg mifepristone.21 
As this trial ended with hysterectomies and there was no 
plan to repeat treatment in the foreseeable future, it was not 
deemed important to evaluate this aspect.
By way of conclusion we could say that: (1) the differ-
ence in efficacy between the two doses is not huge, since both 
achieve reductions in fibroid and uterine volumes, symptomatic 
improvement, and have minimal side effects, and (2) the 5 mg 
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dose presents the following advantages: (a) slightly greater 
symptomatic improvement, (b) greater speed in the onset of 
this improvement, (c) significant difference in the normalization 
of hemoglobin levels, (d) significantly less irregular bleeding, 
and (e) significantly lower number of dropouts from treatment. 
Part (c) is particularly important when the subject finally comes 
to surgery as it enables her to undergo an operation in better 
hematological shape thus decreasing the chances of blood 
transfusions. Therefore, for these reasons, in our opinion, the 
dose to be used in future should be 5 mg.
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